A1388 PRE SURVEY - Driving Toward Better Schizophrenia Care: Finding Another Route in a Complex Disease With Long-Acting Injectable Medications

1.*Please indicate your degree:(Required.)

Other (please specify)

2.Please indicate your specialty:(Required.)

Psychiatry

Primary Care

Other (please specify)

4.Before participating in this activity, how confident are you in your ability to:

Indicate your response using the following scale:(Required.)

5.Which of the following is a primary barrier that contributes to suboptimal utilization of LAI schizophrenia medications?(Required.)

a. Patient attitudes and perceptions

b. Patient not appropriately informed by their clinician

c. Overburdened public health agencies

d. Inconvenience for staff and patients

6.A clinician is preparing to introduce LAI medications to a patient who has been newly diagnosed with schizophrenia. Which option represents the most appropriate way to present LAI treatment?(Required.)

a. “This treatment will keep you on track, so you don’t forget to take your medication and end up in the hospital again.”

b. “This treatment is basically the same medicine as the oral but in shot form.”

c. “Most patients get used to the injection after a while; it’s really not a big deal.”

d. “This treatment delivers medication evenly over time and can reduce relapse and hospitalizations.”

e. “The injection is required only every 2 to 24 weeks, depending on the product.”

7.Which of the following statements best reflects the pharmacologic and safety profile of once-monthly, subcutaneous olanzapine LAI as demonstrated in the phase 3 SOLARIS trial?(Required.)

a. No reported postinjection delirium/sedation syndrome (PDSS) events; adverse events consistent with second-generation antipsychotics

b. No reported PDSS events; no discontinuations due to weight gain

c. A small but significant rate of PDSS was seen, similar to intramuscular olanzapine

d. A small but significant rate of PDSS was seen and <1% of patients discontinued due to weight gain

8.A 2024 real-world analysis of Medicare data from over 150,000 beneficiaries with schizophrenia showed that, compared with oral risperidone, LAI medications were associated with which of the following outcomes?(Required.)

a. Increased adherence; reduced hospitalizations; increased total healthcare costs

b. Increased adherence; reduced hospitalizations and emergency department visits; reduced total healthcare costs

c. Increased adherence; reduced hospitalizations; increased emergency department visits and total healthcare costs

9.Please complete the following:(Required.)

Full Name

Email

10.Please indicate the Regional Meeting you will be attending (Select 1)